World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 98 8782 8243 4526 4185 819 46954

Bradley J. Monk publications per year

The chart shows the history of publications by Bradley J. Monk between 1988 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Bradley J. Monk published across 38 years, from 1988 to 2025, averaging 27.1 papers a year. Output peaked at 115 publications in 2023. 126 of the 1,028 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1988 to 2025. Vertical axis: number of publications, 0 to 115. Peak 115 publications in 2023. 1988: 1 publication 1989: 0 publications 1990: 0 publications 1991: 1 publication 1992: 4 publications 1993: 2 publications 1994: 7 publications 1995: 4 publications 1996: 2 publications 1997: 4 publications 1998: 5 publications 1999: 7 publications 2000: 3 publications 2001: 9 publications 2002: 12 publications 2003: 5 publications 2004: 14 publications 2005: 17 publications 2006: 22 publications 2007: 29 publications 2008: 23 publications 2009: 26 publications 2010: 30 publications 2011: 29 publications 2012: 32 publications 2013: 30 publications 2014: 49 publications 2015: 48 publications 2016: 38 publications 2017: 34 publications 2018: 32 publications 2019: 49 publications 2020: 66 publications 2021: 79 publications 2022: 74 publications 2023: 115 publications 2024: 55 publications 2025: 71 publications
1988 2025

1,028 publications in total across all disciplines

View publications per year as a table
Bradley J. Monk: publications per year, 1988 to 2025
Year Publications
1988 1
1989 0
1990 0
1991 1
1992 4
1993 2
1994 7
1995 4
1996 2
1997 4
1998 5
1999 7
2000 3
2001 9
2002 12
2003 5
2004 14
2005 17
2006 22
2007 29
2008 23
2009 26
2010 30
2011 29
2012 32
2013 30
2014 49
2015 48
2016 38
2017 34
2018 32
2019 49
2020 66
2021 79
2022 74
2023 115
2024 55
2025 71
Total 1,028
Download as CSV

Bradley J. Monk publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bradley J. Monk sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 801–820 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 819 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204 819
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Bradley J. Monk D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bradley J. Monk sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 98–99 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668 98
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Bradley J. Monk is affiliated with the University of Arizona in the United States. Their research focuses primarily on medicine, with a strong emphasis on oncology, reproductive medicine, and obstetrics and gynecology. Additional subfields of study include pulmonary and respiratory medicine as well as surgery.

The scientist's main research topics include:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and cervical cancer treatments
  • PARP inhibition in cancer therapy
  • Cancer immunotherapy and biomarkers
  • Cervical cancer and HPV research
  • Cancer genomics and diagnostics
  • Lung cancer treatments and mutations

Bradley J. Monk has contributed to a variety of journals and publication venues, with the most frequent being:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • The Lancet Oncology

Their recent notable papers include:

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer, 2021, New England Journal of Medicine
  • Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, 2023, New England Journal of Medicine
  • Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study, 2021, The Lancet Oncology
  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet Oncology
  • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45), 2022, Journal of Clinical Oncology

Throughout their career, the scientist has frequently collaborated with several colleagues, including:

  • Robert L. Coleman
  • David M. O'Malley
  • Krishnansu S. Tewari
  • Kathleen N. Moore
  • Domenica Lorusso

Best Publications

  • Incorporation of bevacizumab in the primary treatment of ovarian cancer

    Robert A. Burger;Mark F. Brady;Michael A. Bookman;Gini F. Fleming

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René DePont Christensen

  • Improved Survival with Bevacizumab in Advanced Cervical Cancer

    Krishnansu S. Tewari;Michael W. Sill;Harry J. Long;Richard T. Penson

  • Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René De Pont Christensen

  • Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

    Robert A. Burger;Michael W. Sill;Bradley J. Monk;Benjamin E. Greer

  • Carcinogenic human papillomavirus infection.

    Mark Schiffman;John Doorbar;Nicolas Wentzensen;Silvia de Sanjosé

  • Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

    John B. Welsh;Patrick P. Zarrinkar;Lisa M. Sapinoso;Suzanne G. Kern

  • Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

    Bradley J. Monk;Michael W. Sill;D. Scott McMeekin;David E. Cohn

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Nicoletta Colombo;Coraline Dubot;Domenica Lorusso;M Valeria Caceres

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

    Krishnansu S. Tewari;Michael W. Sill;Richard T. Penson;Helen Huang

  • Latest research and treatment of advanced-stage epithelial ovarian cancer

    Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Adhesions after extensive gynecologic surgery: Clinical significance, etiology, and prevention * ** *

    Bradley J. Monk;Michael L. Berman;F.J. Montz

  • Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

    Bradley J. Monk;Michael W. Sill;Robert A. Burger;Heidi J. Gray

  • Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    John K. Chan;Mark F. Brady;Richard T. Penson;Helen Huang

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

Frequent Co-Authors

Thomas J. Herzog
Thomas J. Herzog University of Cincinnati
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
David M. O'Malley
David M. O'Malley The Ohio State University
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Robert S. Mannel
Robert S. Mannel University of Oklahoma Health Sciences Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean following the traditional route to become a doctor. Many students consider related fields that offer rewarding, impactful opportunities with flexible online learning options. Programs such as adn programs (Associate Degree in Nursing) provide a practical pathway to becoming a registered nurse in less time than a full bachelor’s degree.

Those interested in administrative roles can benefit from accelerated healthcare programs offered online, helping you enter the workforce quickly. Additionally, online medical coding classes with financial aid can open doors to essential roles in the growing field of healthcare information management, with minimal upfront costs.

For those seeking less competitive entry requirements, there are nursing schools that don't require teas or hesi exams, reducing barriers to admission and attracting a wider range of applicants. These options highlight how students can pursue diverse, valuable healthcare careers through accessible and flexible education paths beyond medical school.

Best Scientists Citing Bradley J. Monk

Trending Scientists

Recently Published Articles